Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether levamisole changes maximal mouth opening (interincisal distance) compared with antioxidant (Antoxid) (very low certainty).
2 findings from 1 review
Burning sensation (VAS 0-100) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether levamisole changes burning sensation (VAS 0-100) compared with antioxidant (Antoxid) (very low certainty).
2 findings from 1 review
Relapse during treatment (4 to 12 months) · SSNS in children
Levamisole may leads to lower relapse during treatment (4 to 12 months) compared with steroids or placebo or both, or no treatment (low certainty).
1 finding from 1 review
Clinical relapse · SSNS in children
Levamisole may leads to lower relapse at 6 to 12 months compared with steroids or placebo or both, or no treatment (low certainty).
1 finding from 1 review
Frequent relapses · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean relapse rate/patient/month · SSNS in children
1 finding from 1 review
Adverse effects: leucopenia · SSNS in children
Levamisole showed no clear difference in adverse effects: leucopenia compared with steroids or placebo or both, or no treatment (low certainty).
1 finding from 1 review
Adverse effects: ANCA positive/arthritis · SSNS in children
Levamisole showed no clear difference in adverse effects: ANCA positive/arthritis compared with steroids or placebo or both, or no treatment (low certainty).
1 finding from 1 review
Relapse · SSNS in children
It is very uncertain whether levamisole changes relapse: at end of therapy compared with cyclophosphamide (very low certainty).
4 findings from 1 review
RR 2.14 [0.22, 20.95]
2 studies · 97 participants
Very low
RR 1.17 [0.76, 1.81]
2 studies · 97 participants
Low
RR 0.89 [0.68, 1.16]
1 study · 40 participants
Low
Show 1 more finding
Frequent relapses · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean relapse rate/patient/month · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: infection · SSNS in children
Levamisole showed no clear difference in adverse effects: infection compared with cyclophosphamide (low certainty).
1 finding from 1 review
Adverse effects: leucopenia · SSNS in children
Levamisole showed no clear difference in adverse effects: leucopenia compared with cyclophosphamide (low certainty).
1 finding from 1 review
Adverse effects: abnormal liver function tests · SSNS in children
It is very uncertain whether levamisole changes adverse effects: abnormal liver function tests compared with cyclophosphamide (very low certainty).
1 finding from 1 review
Incidence of herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis
1 finding from 1 review
Adverse effects during use of the preventative intervention (leading to discontinuation) · participants with recurrent herpes labialis
1 finding from 1 review
Duration of attack of recurrent herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis
1 finding from 1 review
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Effectiveness · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Relief of pain · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Levamisole (150 mg per day) showed no clear difference in decrease in pain compared with placebo; GRADE not reported.
1 finding from 1 review
RR 4.29 [0.67, 27.24]
1 study
GRADE not reported